C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so, will the doctors catch it at an early enough stage? C2i Genomics has developed software that’s 100x more sensitive in detecting residual disease, and investors are pouncing on the potential. Today, C2i announced a $100 million Series B led by Casdin Capital.
“The biggest question in cancer treatment is, ‘Is it working?’ Some patients are getting treatment they don’t benefit from and they are suffering the side effects while other patients are not getting the treatment they need,” said Asaf Zviran, co-founder and CEO of C2i Genomics in an interview.
C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing.
The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management, and LionBird.
The company intends to use the funds to accelerate clinical development and commercialization of its C2-Intelligence Platform and to deepen its partnerships with pharmaceutical companies.
Led by Asaf Zviran, co-founder and CEO, C2i provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease.
Nine out of ten Danes say that they will accept the COVID-19 vaccine when offered. This is the same level as before the AstraZeneca vaccine was paused.
E-Mail
The unpopular guests are already here. Hazel-, alder- and elm tree pollen sweep in over us during the early spring months, with birch pollen following in May. Then grass follows in June-July before mugwort pollen closes the season in late summer. All leading to more and more people suffering.
Over fifty years, the proportion of young Danes who sneeze, rub itchy eyes or suffer a blocked nose because of pollen has grown from 7-8 per cent in the 1970s to 24 per cent today. And for asthma, the proportion has risen from 4 to 12 per cent during the same period. This is shown by a study of 53,000 Danish blood donors published by researchers from Aarhus University in collaboration with the Blood Bank at Aarhus University Hospital.
Hay fever and asthma affect more people, and earlier – TodayHeadline todayheadline.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from todayheadline.co Daily Mail and Mail on Sunday newspapers.